==Pharmacology==
...or the [[angiotensin II receptor type 1]] (AT<sub>1</sub>), with a binding affinity 3000 times greater for AT<sub>1</sub> than [[Angiotensin II receptor type 2
...
8 KB (1,021 words) - 16:03, 28 March 2024
==Pharmacology== <!--T:15-->
...or the [[angiotensin II receptor type 1]] (AT<sub>1</sub>), with a binding affinity 3000 times greater for AT<sub>1</sub> than [[Angiotensin II receptor type 2
...
8 KB (1,075 words) - 16:02, 28 March 2024
==Pharmacology==
...sis is not well understood. However, it has been shown to have comparable affinity with calcitriol for the [[vitamin D receptor]] (VDR), while being less than
...
7 KB (918 words) - 22:41, 12 April 2024
==Pharmacology== <!--T:20-->
...sis is not well understood. However, it has been shown to have comparable affinity with calcitriol for the [[vitamin D receptor]] (VDR), while being less than
...
8 KB (978 words) - 22:40, 12 April 2024
...ood exists in two forms: bound and unbound. Depending on a specific drug's affinity for [[plasma protein]]s, a proportion of the drug may become bound to the p
...iley.com/10.1046/j.1365-2885.2002.00442.x |journal=[[Journal of Veterinary Pharmacology and Therapeutics]] |publisher= Wiley inc.|volume=25 |issue=6 |pages=460–463
...
8 KB (1,201 words) - 12:11, 15 November 2023
...a pharmacology")|Materia medica|the journal|Karger Publishers#Journals{{!}}Pharmacology (journal)}}
...Pharmacology and Experimental Therapeutics newsletter|American Society for Pharmacology and Experimental Therapeutics#Publications{{!}}The Pharmacologist}}
...
30 KB (3,998 words) - 20:36, 8 January 2023
...rs, which they published in 1995. These compounds had excellent [[potency (pharmacology)|potency]] and improved chemical stability.
...bined with several exposed [[aromatic]] [[side chain]]s for achieving high affinity small molecule binding.
...
32 KB (4,417 words) - 10:31, 12 March 2024
...le]]-5-acetic acid derivatives. S-8307 and S-8308 have moderate [[Potency (pharmacology)|potency]], short duration of action and limited oral bioavailability, howe
...ety the compound EXP-6803 was synthesized. It had highly increased binding affinity but was only active when administered [[intravenously]].
...
22 KB (3,221 words) - 10:25, 28 March 2024
...rs, which they published in 1995. These compounds had excellent [[potency (pharmacology)|potency]] and improved chemical stability.
...bined with several exposed [[aromatic]] [[side chain]]s for achieving high affinity small molecule binding.
...
33 KB (4,561 words) - 10:30, 12 March 2024
...le]]-5-acetic acid derivatives. S-8307 and S-8308 have moderate [[Potency (pharmacology)|potency]], short duration of action and limited oral bioavailability, howe
...ety the compound EXP-6803 was synthesized. It had highly increased binding affinity but was only active when administered [[intravenously]].
...
22 KB (3,315 words) - 10:25, 28 March 2024
===AT<sub>1</sub> affinity vs AT<sub>2</sub>===
...inities of the specific ARBs are shown as follows. However, AT<sub>1</sub> affinity vs AT<sub>2</sub> is not a meaningful indicator of blood pressure response.
...
19 KB (2,554 words) - 18:03, 25 March 2024
...a pharmacology")|Materia medica|the journal|Karger Publishers#Journals{{!}}Pharmacology (journal)}}
...Pharmacology and Experimental Therapeutics newsletter|American Society for Pharmacology and Experimental Therapeutics#Publications{{!}}The Pharmacologist}}
...
46 KB (5,967 words) - 12:23, 15 November 2023
===AT<sub>1</sub> affinity vs AT<sub>2</sub>=== <!--T:24-->
...inities of the specific ARBs are shown as follows. However, AT<sub>1</sub> affinity vs AT<sub>2</sub> is not a meaningful indicator of blood pressure response.
...
20 KB (2,701 words) - 21:51, 21 April 2024
...7 half-lives. }}</ref><ref>{{cite journal | journal= Journal of Veterinary Pharmacology and Therapeutics| volume=27 | issue=6 | pages=427–439 | date=2004 | quote=F
...e full blood of an [[organism]]. This measurement is useful in medicine, [[pharmacology]] and [[pharmacokinetics]] because it helps determine how much of a drug ne
...
23 KB (3,078 words) - 12:12, 15 November 2023
{{Redirect/ja|Pharmaceutical/ja||Pharmacy/ja|と|Pharmacology/ja|と|Pharmaceutical industry/ja}}
薬物治療（[[pharmacotherapy/ja|薬物療法]]）は[[medicine/ja|医療分野]]の重要な一部であり、継続的な進歩のために[[pharmacology/ja|薬学]]の科学に、適切な管理のために[[pharmacy/ja|薬局]]に依存するものである。
...
58 KB (1,845 words) - 17:09, 5 November 2023
| Section6 = {{Chembox Pharmacology
...iferol. Calcifediol is better absorbed from the intestine and has greater affinity for the vitamin-D-binding protein, both of which increase its bioavailabili
...
10 KB (1,460 words) - 20:39, 12 April 2024
| Section6 = {{Chembox Pharmacology
...iferol. Calcifediol is better absorbed from the intestine and has greater affinity for the vitamin-D-binding protein, both of which increase its bioavailabili
...
11 KB (1,502 words) - 20:39, 12 April 2024
In the fields of medicine, [[biotechnology]] and [[pharmacology]], '''drug discovery''' is the process by which new candidate [[pharmaceuti
...h are hypothesized to be disease-modifying in a process known as [[reverse pharmacology]]. Hits from these screens are then tested in cells and then in animals for
...
55 KB (7,244 words) - 08:05, 4 January 2023
{{Redirect|Pharmaceutical||Pharmacy|and|Pharmacology|and|Pharmaceutical industry}}
...the [[medicine|medical field]] and relies on the science of [[pharmacology|pharmacology]] for continual advancement and on [[pharmacy|pharmacy]] for appropriate ma
...
52 KB (6,923 words) - 17:09, 5 November 2023
{{Short description|Branch of pharmacology}}
...chemical kinetics]]), sometimes abbreviated as '''PK''', is a branch of [[pharmacology]] dedicated to describing how the body affects a specific substance after a
...
44 KB (6,066 words) - 12:21, 15 November 2023